Sana Biotechnology Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Sana Biotechnology is de winst gegroeid met een gemiddeld jaarlijks percentage van 7.2%, terwijl de Biotechs industrie de winst growing met 34.1% per jaar.

Belangrijke informatie

7.20%

Groei van de winst

24.06%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.04%
Inkomstengroei	n/a
Rendement op eigen vermogen	-137.04%
Nettomarge	n/a
Laatste winstupdate	30 Jun 2026

Recente prestatie-updates uit het verleden

Recent updates

Seeking Alpha • Jul 22

Sana Biotechnology: A $1 Billion Market Cap Built On A Pre-Phase 1 Foundation

Summary Sana Biotechnology is rated Sell due to excessive risk and overvaluation relative to its early-stage pipeline. Both lead assets, SC291 and SC451, are years from market and face low historical success rates, with SC291 only in Phase 1. The entire pipeline depends on the unproven Hypoimmune (HIP) platform; failure in early trials could invalidate the company. With $128.9M in cash and high burn, heavy dilution is likely for SANA, making the current $3.14 share price unjustified versus a $0.53 risk-adjusted fair value. Read the full article on Seeking Alpha

Seeking Alpha • Mar 25

Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421

Summary SANA develops engineered cell therapies for diabetes, autoimmune diseases, and cancer using ex vivo HIP and in vivo fusogen platforms. SC291 is their CD19‑targeted allogeneic CAR-T candidate which also received FDA Fast Track for r/r SLE, extrarenal lupus, and lupus nephritis. However, UP421 might be the most promising. It restored insulin production in a type 1 diabetes patient. SANA also has ongoing Phase 1 trials for SC291 and SC262, with topline data expected in 2025. However, SANA does have high cash burn and dilution risks, which is why I just rate it a speculative “Buy”. Read the full article on Seeking Alpha

Seeking Alpha • Jan 08

Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success

Summary Sana Biotechnology, Inc. stock will be surging today after the company showed it can safely administer its allogeneic cell therapy for diabetes to a patient with no immunosuppression. Engineered cells were accepted by the patient's immune system without immunosuppression, a potential game-changing breakthrough that has stumped scientists for >75 years. Although the data is from a single patient, the potential market opportunity for a functional cure for Type 1 diabetes is immense. I rate SANA stock as a “Buy,” but advise caution as the stock may correct downward before long-term growth, given the early stage of clinical progress. Read the full article on Seeking Alpha

Seeking Alpha • Dec 04

Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus

Summary Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025. The FDA's Fast Track Designation for SC291 could expedite its review, addressing unmet medical needs in autoimmune disorders. Sana is also developing SC262 for relapsed/refractory B-cell malignancies, with data expected by the end of 2024 or in 2025. The global Lupus drugs market is expected to reach $4.2 billion by 2031. Read the full article on Seeking Alpha

Seeking Alpha • Nov 19

Sana Biotechnology: The Story Becomes Murkier

Summary Sana Biotechnology, Inc.'s stock has dropped from around $9 to under $2.50 since mid-March, when we last took a look at this engineered-cell therapy concern. Earlier this month, the company suspended two of its developmental programs to improve its pipeline focus and lower its cash burn rate to extend its “cash runway.”. The analyst community is also quite mixed around Sana Biotechnology's current prospects, but some additional trial data should be posted in the near future. An updated analysis around Sana Biotechnology follows in the paragraphs below. Read the full article on Seeking Alpha

Analyse-artikel • Nov 01

We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Seeking Alpha • Jul 14

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

Summary Sana Biotechnology is a biotech company focused on developing engineered allogeneic cells for diseases with unmet clinical needs. Sana's most advanced product candidates leverage CRISPR technology to modify cells, with positive pre-clinical trial results and first in-human trials starting in late 2023. The company's pipeline includes oncology, autoimmune disease, and regenerative medicine product candidates, with a focus on UP421 and SC291 for T1DM and B-cell malignancies, respectively. Read the full article on Seeking Alpha

Analyse-artikel • Jul 12

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Seeking Alpha • Mar 17

Sana Biotechnology: Now In Overbought Territory

Summary Sana Biotechnology's shares have risen some 60% since a secondary offering in February, driven by positive early clinical and research results. The company is focused on developing engineered cells to treat diseases, using a hypoimmune technology platform to create cells that evade immune detection. Sana has three clinical programs in Phase 1 trials, with promising results seen in the treatment of B-cell cancer and type I diabetes. A full analysis around Sana Biotechnology follows in the paragraphs below. Read the full article on Seeking Alpha

Seeking Alpha • Jan 11

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Summary Sana Biotechnology's novel T1D treatment, not requiring immunosuppression, shows encouraging results in a non-human primate study. Sana displays improved Q3 financials with a current ratio of 4.03, but faces high cash burn and potential funding needs. Investment Stance: Shift from "Sell" to "Hold" based on Sana's financial management and R&D progress, with a watchful eye for further clinical and financial developments. Read the full article on Seeking Alpha

Analyse-artikel • Dec 30

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Analyse-artikel • Sep 14

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyse-artikel • May 26

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyse-artikel • Dec 19

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analyse-artikel • Sep 03

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Seeking Alpha • Jun 27

Sana Biotechnology A Buy For Potential Cancer Therapies

Preclinical stage company has cash, expertise, and platform for success. Recent preclinical data showed potential of its technology. Clinical trials could begin in 2023, following INDs in 2022.

Analyse-artikel • May 16

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Opbrengsten en kosten

Hoe Sana Biotechnology geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:SANA Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 26	-212	45	140
31 Mar 26	-242	44	136
31 Dec 25	-244	44	147
30 Sep 25	-234	49	141
30 Jun 25	-252	53	153
31 Mar 25	-209	59	156
31 Dec 24	-267	64	207
30 Sep 24	-306	68	229
30 Jun 24	-245	73	223
31 Mar 24	-309	73	281
31 Dec 23	-283	73	254
30 Sep 23	-276	67	246
30 Jun 23	-362	63	284
31 Mar 23	-320	61	248
31 Dec 22	-269	67	204
30 Sep 22	-300	56	232
30 Jun 22	-298	54	232
31 Mar 22	-207	53	135
31 Dec 21	-356	50	275
30 Sep 21	-358	47	266
30 Jun 21	-327	41	230
31 Mar 21	-433	34	336
31 Dec 20	-285	28	232
30 Sep 20	-215	25	174
31 Dec 19	-131	22	102

Kwaliteitswinsten: SANA is momenteel verliesgevend.

Groeiende winstmarge: SANA is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: SANA is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 7.2% per jaar verminderd.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van SANA over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: SANA is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 64.6% ).

Rendement op eigen vermogen

Hoge ROE: SANA heeft een negatief Return on Equity ( -137.04% ), omdat het momenteel verliesgevend is.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/08/20 03:19
Aandelenkoers aan het einde van de dag	2026/08/20 00:00
Inkomsten	2026/06/30
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Sana Biotechnology, Inc. wordt gevolgd door 12 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Alec Stranahan	BofA Global Research
Samantha Lynn Semenkow	Citigroup Inc
Reni Benjamin	Citizens JMP Securities, LLC

Sana Biotechnology Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Sana Biotechnology, Inc. Announces Impairment of Long-Lived Assets for the Three Months Ended June 30, 2025

Recent updates

New major risk - Financial position

Sana Biotechnology Secures Mayo Clinic Backing and $25 Million for Diabetes Cell Therapy

Sana Biotechnology: A $1 Billion Market Cap Built On A Pre-Phase 1 Foundation

Sana Biotechnology Announces Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes

Sana Biotechnology to Unveil First Human UP421 Islet Cell Therapy Data at EASD 2026

Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 3000 Value Benchmark

New major risk - Shareholder dilution

Sana Biotechnology Presents Preclinical Data for in Vivo Car T Cell Therapy Sg293 Surrogate Demonstrating Cell-Specific Delivery, Potent Car T Cell Generation, and Deep B Cell Depletion in Nhps

Sana Biotechnology, Inc., Annual General Meeting, Jun 04, 2026

Sana Biotechnology Announces Continued Positive Clinical Results From Type 1 Diabetes Study Of Islet Cell Transplantation Without Immunosuppression

New major risk - Financial position

Sana Biotechnology, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Sana Biotechnology, Inc. Announces Executive Changes

New major risk - Share price stability

New major risk - Financial position

Sana Biotechnology, Inc. Announces Executive Changes, Effective October 20, 2025

Sana Biotechnology, Inc. Announces Resignation of Mary Agnes Wilderotter from Board, Chairperson of the Nominating and Corporate Governance Committee of the Board and A Member of the Audit Committee of the Board, Effective August 29, 2025

New minor risk - Shareholder dilution

Price target decreased by 7.0% to US$8.83

Sana Biotechnology, Inc. Announces Impairment of Long-Lived Assets for the Three Months Ended June 30, 2025

Sana Biotechnology, Inc. Announces Resignation of Sonja Schrepfer as Senior Vice President and Head of the Hypoimmune Platform

New major risk - Share price stability

Sana Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $74.999848 million.

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Sana Biotechnology, Inc. has filed a Follow-on Equity Offering in the amount of $119 million.

Pomerantz Law Firm Announces the Filing of Class Action Against Sana Biotechnology, Inc. and Certain Officers

Sana Biotechnology, Inc., Annual General Meeting, Jun 05, 2025

Robbins LLP Files Class Action Lawsuit Against Sana Biotechnology, Inc

Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421

New major risk - Financial position

New major risk - Share price stability

Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success

Sana Biotechnology, Inc. Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Price target decreased by 8.0% to US$9.20

Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus

Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus

Sana Biotechnology: The Story Becomes Murkier

Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-Cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025

We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully

Vice Chairman notifies of intention to sell stock

Sana Biotechnology, Inc. Announces Resignation of Nathan Hardy as Executive Vice President, Effective October 4, 2024

Sana Biotechnology, Inc. Announces the Appointment of Dhaval Patel as Executive Vice President and Chief Scientific Officer

New minor risk - Financial position

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 2000 Value Index

Price target increased by 9.3% to US$12.20

New major risk - Revenue and earnings growth

Sana Biotechnology, Inc. Highlights Publication in Nature Biotechnology of Novel in Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as A Treatment for Huntington's Disease and Other Glial-Based Neurodegenerative Conditions

Sana Biotechnology, Inc., Annual General Meeting, Jun 06, 2024

Sana Biotechnology: Now In Overbought Territory

Independent Director recently sold US$236k worth of stock

Price target increased by 17% to US$10.50

Sana Biotechnology, Inc. Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in Diabetic NHP

Sana Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $164.998727 million.

Sana Biotechnology, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Sana Biotechnology, Inc. Announces FDA Clearance of Investigational New Drug Application for SC262

Insufficient new directors

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Executive VP & Chief Business Officer notifies of intention to sell stock

Sana Biotechnology, Inc. Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic Car T Cells in Presentations At the American Society of Hematology Annual Meeting

Sana Biotechnology Publishes Early Clinical Data Showing That Sc291, A Cd19-Directed Allogeneic Car T Therapy, Evades Immune Detection in Presence of Intact Immune System

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for Sc291, A Hypoimmune-Modified, Cd19-Directed Allogeneic Car T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and Anca-Associated Vasculitis

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Sana Biotechnology, Inc. Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with A 2024 Operating Burn Under $200M

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Price target increased by 8.6% to US$9.50

New major risk - Revenue and earnings growth

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

Price target decreased by 10% to US$8.75

Sana Biotechnology, Inc. Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate